Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Illustrative photo Boehringer Ingelheim Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast ...
BioSpace17h
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
The Pharma Letter19h
Boehringer’s nerandomilast meets endpoint in Phase III study
Boehringer Ingelheim today revealed that the FIBRONEER-ILD trial of nerandomilast met its primary endpoint, which was the ...
Orca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.
Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming
Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...
Boehringer Ingelheim Limited: Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...
Endpoint Security: How It Protects Your Business from Cyber Threats
In today digital landscape businesses face an increasing number of cyber threats with endpoints being a primary target Endpoint security plays a crucial role in safeguarding organizations from cyberat ...
TMCnet20h
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine. New Drug Application (NDA) Submission Expected in the ...
EyePoint announces Phase 2 VERONA trial met primary endpoint
Pharmaceuticals announced positive six-month results for the ongoing Phase 2 VERONA clinical trial evaluating DURAVYU, an ...
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...